. Bone metastases occur in approximately 85% of patients who die of the disease (McCrea et al., 1958; Jacobs et al., 1983) . Although bone-forming metast are charactenrstic of prostate cancer, bone resorption is also accelerated, as evidenced by an increase in the urinary hydroxyproline excretion and by the presence of lytic bone lesions in radiographs (Hopkins et al., 1983; Urwin et al., 1985; Percival et al., 1987; Shimazaki et al., 1990) . Also, histomorphometnrc examination of skeletal biopsies has confirmed an enhanced osteolysis (Charhon et al., 1983; Urwin et al., 1985; Clarke et al., 1992; Taube et al., 1994) . The main symptom of bone metastases is pain, but lytic lesions may sometimes also lead to pathological fractures and hypercalcaemia. Although most patients with bony metastases respond to the first-line hormonal therapy, the median survival is between 2 and 3 years, and only 30% are alive after 5 years (Murphy et al., 1983) .
At the time of diagnosis of prostate cancer the tumour has advanced beyond the prostatic capsule in 75% of the patients, and distant metastases can be detected in nearly half (Klein, 1979; Elder and Catalona, 1984) . Bone metastases occur in approximately 85% of patients who die of the disease (McCrea et al., 1958; Jacobs et al., 1983) . Although bone-forming metast are charactenrstic of prostate cancer, bone resorption is also accelerated, as evidenced by an increase in the urinary hydroxyproline excretion and by the presence of lytic bone lesions in radiographs (Hopkins et al., 1983; Urwin et al., 1985; Percival et al., 1987; Shimazaki et al., 1990) . Also, histomorphometnrc examination of skeletal biopsies has confirmed an enhanced osteolysis (Charhon et al., 1983; Urwin et al., 1985; Clarke et al., 1992; Taube et al., 1994) . The main symptom of bone metastases is pain, but lytic lesions may sometimes also lead to pathological fractures and hypercalcaemia. Although most patients with bony metastases respond to the first-line hormonal therapy, the median survival is between 2 and 3 years, and only 30% are alive after 5 years (Murphy et al., 1983) .
The major structural protein in bone is type I collagen, which is synthesised by osteoblasts and accounts for about 90% of the organic matrix of bone (Risteli et al., 1993 (1988) . The types of metastases were evaluated by radiographs, which showed sclerotic metastases without a visible lytic component (S) in 23 patients (58%) and mixed metastases with sclerotic and lytic components (S + L) in 17 patients (42%). Intermittent or constant bone pain had led to Figure 1 . Each of the values was above the reference interval in the S + L group, whereas in the S group the ICTP levels were increased in half of the patients and 35% of the patients had high PICP and AP values. The mean concentrations of ICTP, PICP and AP were significantly higher in the S + L group than in the S group (P<0.0001, P<0.0001, P<0.001 respectively) ( Table II) . The fewer bone metastases the patient had the lower were the concentrations of various biochemical markers (Table II) . The PSA concentrations were elevated in all patients (Table II) .
Correlations and regressions between biochemical markers In the whole group studied, a significant correlation was observed only between the PICP and AP (r = 0.55, P = 0.001). Of all the markers ICTP was the most important prognostic factor for survival (X2 = 2.93; P = 0.08), followed by PSA, PICP and AP. Of the bone markers, ICTP was the only one with prognostic signiflance (X: = 3.61; P = 0.05).
Survival
The median survival was 27 months for patients with S metastases and 19 months for those with S + L metastases. A significant difference in survival was seen between the groups (Mantel-Cox P=0.017) (Figure 2 ).
We have investigated prostate cancer patients with skeletal metastases at the time of diagnosis. The number of bone metastases was evaluated by bone scan and the nature of the sclerotic or lytic component by radiography. Skeletal metastases can also be investigated with biochemical markers (Francini et al., 1988; Mulders et al., 1989 Mulders et al., , 1992 (Charhon et al., 1985; Urwin et al., 1985) . Another possibility is that the osteolysis may be due to circulating tumour-generated factors such as epidermal growth factor (EGF), transforming growth factor alpha (TGF-a) and platelet-derived growth factor (PDGF), which could promote osteoclast overactivity (Mundy, 1988; Vaes, 1988; Morris and Dodd, 1990 
